Sean T. Smith
Analyst · effect on your gross margin and operating expenses
Thanks, Peter, and good morning, everyone. I'll provide a brief analysis of our financial results for the fourth quarter, review our balance sheet and cash flows, discuss our forecast and also provide additional information on the recently announced Taiwan JV. Please refer to Slide 4 for our GAAP to non-GAAP net income and EPS reconciliation as we review the fourth quarter. For purposes of our discussions, I will be primarily comparing our non-GAAP operating results to the revised fourth quarter guidance we published in our November 13 press release. Slides 5, 6 and 7 show our sequential quarterly and year-to-date IC and FPD revenue performance. Fourth quarter revenue decreased by 3.3% sequentially to $106 million for the reasons Peter discussed. Revenues for IC photomask were $79.8 million, down $4.3 million sequentially for the fourth quarter, while FPD photomask revenue increased 700k sequentially to $26.2 million. Breaking out sales geographically, 62% of total sales were from Asia, 27% from North America and 11% from Europe. High-end global IC sales were $15.6 million or 20% of total IC sales for the quarter. This represents a sequential decrease of $7.3 million. Global mainstream sales increased sequentially by $2.9 million or 5%. Advanced FPD sales increased by $1.8 million to $18.5 million or 71% of total FPD sales. As a reminder, high-end IC revenues consist of revenue derived from semi-designed at and below 45-nanometer, and high-end FPD revenues consist of revenue at and above G8 as well as AMOLED-based products. Now let's continue through the income statement. Gross margin for the fourth quarter was 25.2%, up 50 basis points sequentially. The increase was primarily related to certain manufacturing costs reallocated to R&D as a result of the increased qualification activity. Selling, general and administrative expenses for the fourth quarter were $12.9 million, up sequentially by $900,000, primarily as a result of approximately $800,000 of expenses directly related to the JV. R&D expenses, which consist principally of continued development for our global advanced process technologies and qualifications at advanced nodes, were $6.4 million, up $1.4 million sequentially, primarily as a result of increased qualification activity, including the Asian foundry qual that Peter discussed. During the quarter, we generated operating income of $7.4 million or 7% of sales. Excluding the costs related to the JV, operating income was $8.2 million or 7.7% of sales. Sequentially, operating margin was down 50% of the decreased sales for the quarter. Please turn to Slide 8. EBITDA, as defined in our credit agreement, for the quarter was $26.6 million and for the year was $110 million. Also for the year, free cash flow was $46 million, which is EBITDA of $110 million less our non-financed cash CapEx of $64 million. Other income and expense for the fourth quarter was expense of $1.4 million, up $400,000, sequentially. And during the fourth quarter, we recorded a tax provision of $1.1 million. GAAP net income was $4.8 million or $0.08 per diluted share and non-GAAP net income, excluding the JV transaction expenses, was $5.6 million or $0.09 per diluted share, higher than our revised guidance of $0.06 to $0.07 per share. At the end of the fourth quarter, we have 1,300 full time employees, which was essentially flat with the end of 2012. This equates to revenue per employee of $326,000 on an annualized basis. Now turning to the balance sheet. Despite missing our initial guidance and decreased sequential operating results, our balance sheet actually improved sequentially. Cash and cash equivalents at year-end amounted to $216 million and our net cash, which is cash less debt, was $22 million or up $18 million sequentially. Our working capital at the end of the quarter was $214 million, which was up $22 million sequentially compared to Q3. And accounts payable and accrued current liabilities at year-end amounted to $93 million. And at the end of the quarter, $90 million of CapEx was accrued for, down $11 million from the third quarter of 2013. Please turn to Slide 9 as we review our capitalization. As Deno mentioned, on December 5, we announced we entered into a 5-year $50 million revolving credit facility and the repayment of a $21 million term loan, which was previously due in 2017. The new credit facility provides for increased financial flexibility, reduced interest rates and relaxed financial covenants. Total debt at the end of the year was $194 million, of which $21 million was paid on December 5 as part of the new revolving agreement. The principal components of outstanding pro forma debt include: $22 million of a 5.5% senior unsecured convertible note due in October of 2014; $115 million, 3.25% senior unsecured note due in April 2016; approximately $11 million for capital lease obligation; and approximately $25 million related to a capital lease for an e-beam tool. As of today, we do not have any borrowings outstanding on our new 5-year $50 million credit agreement. Taking a look at our cash flows. Cash provided by operations for the fourth quarter was approximately $32 million. Depreciation and amortization was $17.9 million for the quarter. And for fiscal 2013, cash provided by operations was $99 million. Cash flow used in investing activities during 2013 amounted to $16 million and $66 million for 2013. In fiscal 2013, cash used in investing activities includes $64 million of cash CapEx. Net cash used by financing activities during the quarter, amounted to $4 million and $40 million for fiscal 2013, of which $32 million related to the PSMC take-private transaction that Deno discussed and $8 million related to repayments of debt. Please refer to Slide 10 and 11. On November 20, we announced the formation of a noncash joint venture with DNP in Taiwan. In essence, DNP will be merged with DNP's -- PSMC will be merged with DNP's Taiwan subsidiary, DPTT. The joint venture is subject to regulatory approvals and closing conditions and is projected to be finalized in the first half of fiscal 2014. Let me highlight some of the key provisions of the JV. Photronics will own 50.01% and consolidate the JV in our financial statements. Photronics will manage and control the JV. This is absolutely critical to our ability to be successful with our high-end strategy. We estimate that our top line will grow by at least $80 million annually, with the vast majority of revenue being comprised of high-end IC products. The JV will have a well-capitalized balance sheet and should be self-sufficient. During the quarter, we did incur approximately $800,000 in expenses related to the transaction. And we expect to incur $1 million to $2 million in additional expenses related to the JV prior to the closure. We do expect to extract annual cash synergies of at least $5 million to $7 million beginning within 2 quarters of the JV formation, and we expect the JV to have an accretive impact to the bottom line and EBITDA in fiscal year 2015, if not sooner. Please turn to Slide 12 as we take a look ahead. We expect our cash CapEx needs for 2014 to be in the range of $70 million to $90 million. We do, however, have the flexibility to accelerate or decelerate our spend depending on market conditions. We expect to continue to generate free cash flow once again in 2014. And our 2014 investments will principally be geared towards high-end leading-edge products for IC and FPD applications. Our visibility, as always, continues to be limited as our backlog is typically 1 to 2 weeks. For Q1 2014, we do expect to experience some reduced orders related to the typical year-end holiday seasonality. So taking this all into consideration, we are projecting revenue for the first quarter of 2014 to be in the range of $103 million to $107 million. During 2014, our tax rate will be affected by the flow of income from jurisdictions for which we may have tax credits and upon our limited ability to recognize tax benefits in the areas in which we are taxable. For the first quarter of fiscal 2014, this will equate to a range of $1 million to $2.5 million. For fiscal 2014, we estimate total taxes will range from $12 million to $15 million. As a result, based upon our current operating model, we estimate earnings per share, exclusive of any JV transaction costs for the first quarter of 2014, to be in the range of $0.06 to $0.10 per diluted share. In summary, I'll leave you with a few key thoughts. First, we expect the top and bottom line improvement in 2014 and to continue to expect to generate free cash flow. Second, we are confident about our business model and our ability to grow market share at the high-end. We see continued opportunities in our customers' businesses and node migration plans, and we have a strong financial position and excellent technology to capitalize on those plans. And finally, we expect to continue to build on the momentum that we have established over the past few years as a leader in advanced photomask technology. Now I'd like to turn the call over to the operator for questions and answers.